Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshito Takeda

Showing results (101-110 of 147) with videos related to

Pageof 15
Sort By:
Cancer Science|January 30, 2026
Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical OutcomesKinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2018
Lysosomal Protein Lamtor1 Controls Innate Immune Responses via Nuclear Translocation of Transcription Factor EBYoshitomo Hayama, Tetsuya Kimura, Yoshito Takeda, et al.
Nature Communications|April 28, 2025
Dissecting cross-population polygenic heterogeneity across respiratory and cardiometabolic diseasesYuji Yamamoto, Yuya Shirai, Kyuto Sonehara, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort studyYuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Plos One|September 17, 2013
Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophagesYingji Jin, Isao Tachibana, Yoshito Takeda, et al.
Cancer Science|February 9, 2010
High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organAyako Murao, Yoshihiro Oka, Akihiro Tsuboi, et al.
The Journal of Biological Chemistry|December 11, 2012
Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitroTakeo Iwasaki, Yoshito Takeda, Kazuichi Maruyama, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2024
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative studyKinnosuke Matsumoto, Takayuki Shiroyama, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort studyNao Shoshihara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Respiratory Medicine|April 23, 2026
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapyHirotomo Machiyama, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Pageof 15

Showing results (101-110 of 147) with videos related to

Sort By:
Pageof 15
Cancer Science|January 30, 2026
Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical OutcomesKinnosuke Matsumoto, Yujiro Naito, Takayuki Shiroyama, et al.
Journal of Immunology (Baltimore, Md. : 1950)|April 25, 2018
Lysosomal Protein Lamtor1 Controls Innate Immune Responses via Nuclear Translocation of Transcription Factor EBYoshitomo Hayama, Tetsuya Kimura, Yoshito Takeda, et al.
Nature Communications|April 28, 2025
Dissecting cross-population polygenic heterogeneity across respiratory and cardiometabolic diseasesYuji Yamamoto, Yuya Shirai, Kyuto Sonehara, et al.
Lung Cancer (Amsterdam, Netherlands)|February 22, 2026
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort studyYuhei Kinehara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Plos One|September 17, 2013
Statins decrease lung inflammation in mice by upregulating tetraspanin CD9 in macrophagesYingji Jin, Isao Tachibana, Yoshito Takeda, et al.
Cancer Science|February 9, 2010
High frequencies of less differentiated and more proliferative WT1-specific CD8+ T cells in bone marrow in tumor-bearing patients: an important role of bone marrow as a secondary lymphoid organAyako Murao, Yoshihiro Oka, Akihiro Tsuboi, et al.
The Journal of Biological Chemistry|December 11, 2012
Deletion of tetraspanin CD9 diminishes lymphangiogenesis in vivo and in vitroTakeo Iwasaki, Yoshito Takeda, Kazuichi Maruyama, et al.
Cancer Immunology, Immunotherapy : CII|January 4, 2024
Real-world outcomes of nivolumab plus ipilimumab and pembrolizumab with platinum-based chemotherapy in advanced non-small cell lung cancer: a multicenter retrospective comparative studyKinnosuke Matsumoto, Takayuki Shiroyama, Motohiro Tamiya, et al.
Lung Cancer (Amsterdam, Netherlands)|November 11, 2025
Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort studyNao Shoshihara, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Respiratory Medicine|April 23, 2026
Impact of pre-existing interstitial lung abnormalities on pneumonitis risk and survival in chemo-naive patients with non-small-cell lung cancer receiving pembrolizumab plus chemotherapyHirotomo Machiyama, Kinnosuke Matsumoto, Takayuki Shiroyama, et al.
Pageof 15